![Concerta (Methylphenidate Extended-Release Tablets): Uses, Dosage, Side Effects, Interactions, Warning Concerta (Methylphenidate Extended-Release Tablets): Uses, Dosage, Side Effects, Interactions, Warning](https://images.rxlist.com/images/rxlist/methylphen2.gif)
Concerta (Methylphenidate Extended-Release Tablets): Uses, Dosage, Side Effects, Interactions, Warning
![Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | BMC Psychiatry | Full Text Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | BMC Psychiatry | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-244X-13-237/MediaObjects/12888_2013_Article_1428_Fig4_HTML.jpg)
Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | BMC Psychiatry | Full Text
![Jornay PM (Methylphenidate Hydrochloride Extended-release Capsules ): Uses, Dosage, Side Effects, Interactions, Warning Jornay PM (Methylphenidate Hydrochloride Extended-release Capsules ): Uses, Dosage, Side Effects, Interactions, Warning](https://images.rxlist.com/images/rxlist/jornay-pm3.gif)
Jornay PM (Methylphenidate Hydrochloride Extended-release Capsules ): Uses, Dosage, Side Effects, Interactions, Warning
![Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions | CNS Spectrums | Cambridge Core Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20210622083539525-0708:S1092852919001822:S1092852919001822_tab3.png?pub-status=live)
Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions | CNS Spectrums | Cambridge Core
![My brother is 16 and he has ADHD. What is the right starting dose for medication? – Wayne C Jones, Md My brother is 16 and he has ADHD. What is the right starting dose for medication? – Wayne C Jones, Md](http://askdrjones.com/wp-content/uploads/2007/10/Stimulant-preference-chart.jpg)
My brother is 16 and he has ADHD. What is the right starting dose for medication? – Wayne C Jones, Md
![Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | BMC Psychiatry | Full Text Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | BMC Psychiatry | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-244X-13-237/MediaObjects/12888_2013_Article_1428_Fig5_HTML.jpg)
Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | BMC Psychiatry | Full Text
![A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial - Clinical Therapeutics A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial - Clinical Therapeutics](https://www.clinicaltherapeutics.com/cms/asset/3c6a72fc-d5d9-411c-9e35-e3a9e2f18485/gr2.jpg)
A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial - Clinical Therapeutics
![Stimulant Formulations for the Treatment of Attention-Deficit/Hyperactivity Disorder | Psychiatrist.com Stimulant Formulations for the Treatment of Attention-Deficit/Hyperactivity Disorder | Psychiatrist.com](https://www.psychiatrist.com/PublishingImages/18r02345T1.gif)
Stimulant Formulations for the Treatment of Attention-Deficit/Hyperactivity Disorder | Psychiatrist.com
![Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | BMC Psychiatry | Full Text Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies | BMC Psychiatry | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-244X-13-237/MediaObjects/12888_2013_Article_1428_Fig3_HTML.jpg)